Systems biology in drug discovery and development

Drug Discovery Today

Volumn 19, Issue 2, 2014, Pages 113-125

  Berg, Ellen L ^a  

^a BioSeek Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; NEW DRUG;

CYTOLOGY; DRUG DEVELOPMENT; DRUG EFFECT; DRUG IDENTIFICATION; DRUG MECHANISM; EPIGENETICS; HUMAN; METABOLISM; METABOLOMICS; PERSONALIZED MEDICINE; PREDICTION; PROTEOMICS; REVIEW; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; ANIMAL; BIOLOGICAL MODEL; DRUG DESIGN; HIGH THROUGHPUT SCREENING; PROCEDURES;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, BIOLOGICAL; SYSTEMS BIOLOGY;

EID: 84895922856     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.10.003     Document Type: Review

References (110)

1. L. Hood, and R.M. Perlmutter The impact of systems approaches on biological problems in drug discovery Nat. Biotechnol. 22 2004 1215 1217
2. E.C. Butcher et al. Systems biology in drug discovery Nat. Biotechnol. 22 2004 1253 1259
3. A.-L. Barabási et al. Network medicine: a network-based approach to human disease Nat. Rev. Genet. 12 2011 56 68
4. E.K. Silverman, and J. Loscalzo Network medicine approaches to the genetics of complex diseases Discov. Med. 14 2012 143 152
5. Z. Wang et al. RNA-Seq: a revolutionary tool for transcriptomics Nat. Rev. Genet. 10 2009 57 63
6. A. Kozomara, and S. Griffiths-Jones miRBase: integrating microRNA annotation and deep-sequencing data Nucleic Acids Res. 39 2011 D152 D157
7. A.K. Leung, and P.A. Sharp MicroRNA functions in stress responses Mol. Cell 40 2010 205 215
8. M.V. Iorio, and C.M. Croce Causes and consequences of microRNA dysregulation Cancer J. 18 2012 215 222
9. M. Galasso et al. MicroRNA expression signatures in solid malignancies Cancer J. 18 2012 238 243
10. Q. Tian et al. Integrated genomic and proteomic analyses of gene expression in mammalian cells Mol. Cell. Proteomics 3 2004 960 969
11. A.P. Feinberg Epigenomics reveals a functional genome anatomy and a new approach to common disease Nat. Biotechnol. 28 2010 1049 1052
12. J. Haas et al. Alterations in cardiac DNA methylation in human dilated cardiomyopathy EMBO Mol. Med. 5 2013 413 429
13. A.D. Beggs et al. Whole-genome methylation analysis of benign and malignant colorectal tumours J. Pathol. 229 2013 697 704
14. F. Simmer et al. Comparative genome-wide DNA methylation analysis of colorectal tumor and matched normal tissues Epigenetics 7 2012 1355 1367
15. S.M. Langevin et al. Peripheral blood DNA methylation profiles are indicative of head and neck squamous cell carcinoma: an epigenome-wide association study Epigenetics 7 2012 291 299
16. L. Sigalotti et al. Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients J. Translat. Med. 10 2012 185 10.1186/1479-5876-10-185
17. A. Decock et al. Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers Genome Biol. 13 2012 R95 (Epub ahead of print)
18. Y. Liu et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis Nat. Biotechnol. 31 2013 142 147
19. J. Korlach, and S.W. Turner Going beyond five bases in DNA sequencing Curr. Opin. Struct. Biol. 22 2012 251 261
20. S. Ito et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine Science 333 2011 1300 1303
21. S.R. Langley et al. Proteomics: from single molecules to biological pathways Cardiovascular Res. 97 2013 612 622
22. A. Bensimon et al. Mass spectrometry-based proteomics and network biology Annu. Rev. Biochem. 81 2012 379 405
23. P. Picotti, and R. Aebersold Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions Nat. Methods 9 2012 555 566
24. S.C. Bendall et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum Science 332 2011 687 696
25. K. Varedi et al. Multisite phosphorylation provides an effective and flexible mechanism for switch-like protein degradation PLoS ONE 5 2010 e14029
26. P.A. Grimsrud et al. Phosphoproteomics for the masses ACS Chem. Biol. 5 2010 105 119
27. B. Bodenmiller et al. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators Nat. Biotechnol. 30 2012 858 867
28. P. Minguez et al. PTMcode: a database of known and predicted functional associations between post-translational modifications in proteins Nucleic Acids Res. 41 2012 D306 D311
29. P.V. Hornbeck et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse Nucleic Acids Res. 40 2011 D261 D270
30. H. Dinkel et al. Phospho. ELM: a database of phosphorylation sites: update 2011 Nucleic Acids Res. 39 2011 D261 D267
31. H. Zhou et al. Toward a comprehensive characterization of a human cancer cell phosphoproteome J. Proteome Res. 12 2013 260 271
32. D.S. Wishart et al. HMDB 3.0: The Human Metabolome Database in 2013 Nucleic Acids Res. 41 2013 D801 D807
33. A. Bordbar, and B.O. Palsson Using the reconstructed genome-scale human metabolic network to study physiology and pathology J. Intern. Med. 271 2012 131 141
34. R. Caspi et al. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases Nucleic Acids Res. 40 2011 D742 D753
35. I. Thiele et al. A community-driven global reconstruction of human metabolism Nat. Biotechnol. 31 2013 419 425
36. H. Nam et al. Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification Bioinformatics 25 2009 3151 3157
37. R. Fischer et al. Discovery of candidate serum proteomic and metabolomic biomarkers in ankylosing spondylitis Mol. Cell. Proteomics 11 2012 013904
38. J.M. Stuart et al. A gene-coexpression network for global discovery of conserved genetic modules Science 302 2003 249 255
39. B. Zhang, and S. Horvath A general framework for weighted gene co-expression network analysis Stat. Appl. Genet. Mol. Biol. 4 2005 Article17
40. A.A. Margolin et al. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context BMC Bioinform. 7 2006 S7
41. W. da Huang et al. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists Nucleic Acids Res. 37 2009 1 14
42. M. Kanehisa et al. KEGG for integration and interpretation of large-scale molecular data sets Nucleic Acids Res. 40 2012 D109 D114
43. J. Lamb et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease Science 313 2006 1929 1935
44. X.A. Qu, and D.K. Rajpal Applications of Connectivity Map in drug discovery and development Drug Discov. Today 17 2012 1289 1298
45. A. Ruepp et al. CORUM: the comprehensive resource of mammalian protein complexes Nucleic Acids Res. 36 2007 D646 D650
46. S. Kikugawa et al. PCDq: human protein complex database with quality index which summarizes different levels of evidences of protein complexes predicted from H-invitational protein-protein interactions integrative dataset BMC Syst. Biol. 6 2012 S7 10.1186/1752-0509-6-S2-S7
47. A. Vinayagam et al. Protein complex-based analysis framework for high-throughput data sets Sci. Signal. 6 2013 rs5 10.1126/scisignal.2003629
48. S. Huang, and D.E. Ingber Shape-dependent control of cell growth, differentiation, and apoptosis: switching between attractors in cell regulatory networks Exp. Cell Res. 261 2000 91 103
49. M. K Morris et al. Training signaling pathway maps to biochemical data with constrained fuzzy logic: quantitative analysis of liver cell responses to inflammatory stimuli PLoS Comput. Biol. 7 2011 e1001099
50. R. Kumar et al. Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693 BMC Genomics 11 2010 419
51. J.W. Westra et al. A modular cell-type focused inflammatory process network model for non-diseased pulmonary tissue Bioinform. Biol. Insights 7 2013 167 192
52. W.K. Schlage et al. A computable cellular stress network model for non-diseased pulmonary and cardiovascular tissue BMC Syst. Biol. 5 2011 168
53. A.L. Tarca et al. A novel signaling pathway impact analysis Bioinformatics 25 2008 75 82
54. C.J. Vaske et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM Bioinformatics 26 2010 i237 i245
55. Isci et al. Pathway analysis of high-throughput biological data within a Bayesian network framework Bioinformatics 27 2011 1667 1674
56. L. Li et al. Predicting enzyme targets for cancer drugs by profiling human metabolic reactions in NCI-60 cell lines BMC Bioinform. 11 2010 501
57. A. Ma'ayan, and J.C. He Protein kinase target discovery from genome-wide messenger RNA expression profiling Mt Sinai J. Med. 77 2010 345 349
58. G.R. Abecasis et al. An integrated map of genetic variation from 1,092 human genomes Nature 491 2012 56 65
59. P.M. Visscher et al. Five years of GWAS discovery Am. J. Hum. Genet. 90 2012 7 24
60. W.S. Bush, and J.H. Moore Genome-wide association studies PLoS Comput. Biol. 8 2012 e1002822
61. J. Kim et al. Multi-analyte network markers for tumor prognosis PLoS ONE 7 2012 e52973
62. C.-C. Wu et al. TARGETgene: a tool for identification of potential therapeutic targets in cancer PLoS ONE 7 2012 e43305
63. J.E. McDermott et al. Topological analysis of protein co-abundance networks identifies novel host targets important for HCV infection and pathogenesis BMC Syst. Biol. 6 2012 28
64. S. Suthram et al. Network-based elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets PLoS Comput. Biol. 6 2010 e1000662
65. S.C. Kim et al. A high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokers PLoS ONE 8 2013 e55596
66. The Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours Nature 490 2012 61 70
67. J.A. Lee, and E.L. Berg Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches J. Biomol. Screen. 2013 (in press, PMID: 24080259)
68. T.R. Hughes et al. Functional discovery via a compendium of expression profiles Cell 102 2000 109 126
69. H. Liu et al. mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities Mol. Cancer Ther. 9 2010 1080 1091
70. Y. Liu et al. Multilevel omic data integration in cancer cell lines: advanced annotation and emergent properties BMC Syst. Biol. 7 2013 14
71. R. Radpour et al. Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment PLoS ONE 6 2011 e27355
72. G. Wang et al. Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma PLoS ONE 6 2011 e14573
73. K.M. Hettne et al. Next-generation text-mining mediated generation of chemical response-specific gene sets for interpretation of gene expression data BMC Med. Genomics 6 2013 2
74. K. Komurov et al. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells Mol. Syst. Biol. 8 2012 596
75. C.J. Phillip et al. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells BMC Cancer 12 2012 145
76. Y.Y. Wang et al. Exploring drug combinations in genetic interaction network BMC Bioinform. 13 2012 S7
77. G. Facchetti et al. Predicting and characterizing selective multiple drug treatments for metabolic diseases and cancer BMC Syst. Biol. 6 2012 115
78. F. Pammolli et al. The productivity crisis in pharmaceutical R&D Nat. Rev. Drug Discov. 10 2011 428 438
79. D.C. Swinney, and J. Anthony How were new medicines discovered? Nat. Rev. Drug Discov. 10 2011 507 519
80. J.J. Unternaehrer, and G.Q. Daley Induced pluripotent stem cells for modelling human diseases Philos. Trans. R. Soc. Lond. B 366 2011 2274 2285
81. G. Stacey Current developments in cell culture technology Adv. Exp. Med. Biol. 745 2012 1 13
82. J.W. Haycock 3D cell culture: a review of current approaches and techniques Methods Mol. Biol. 695 2011 1 15
83. E.C. Butcher Can cell systems biology rescue drug discovery? Nat. Rev. Drug Discov. 4 2005 461 467
84. E. Kunkel et al. An integrative biology approach for analysis of drug action in models of human vascular inflammation FASEB J. 18 2004 1279 1281
85. E.L. Berg et al. Characterization of compound mechanisms and secondary activities by BioMAP analysis J. Pharmacol. Toxicol. Methods 53 2006 67 74
86. E.L. Berg et al. Chemical target and pathway toxicity mechanisms defined in primary human cell systems J. Pharmacol. Toxicol. Methods 61 2010 3 15
87. E.L. Berg et al. Biological complexity and drug discovery: a practical systems biology approach Syst. Biol. 152 2005 201 206
88. K.A. Houck et al. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems J. Biomol. Screen. 14 2009 1054 1066
89. E.L. Berg et al. Building predictive models for mechanism of action classification from phenotypic assay datasets J. Biomol. Screen. 2013 (in press, PMID: 24088371)
90. S. Paik Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen Oncologist 12 2007 631 635
91. G. Tang et al. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors J. Clin. Oncol. 29 2011 4365 4372
92. Z. Zhang, and D.W. Chan The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers Cancer Epidemiol. Biomarkers Prev. 19 2010 2995 2999
93. D.S. Cross et al. Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts Curr. Med. Res. Opin. 28 2012 1819 1830
94. Y. Zhang et al. A systems biology-based classifier for hepatocellular carcinoma diagnosis PLoS ONE 6 2011 e22426
95. R. Shaknovich et al. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma Blood 116 2010 e81 e89
96. Y.-A. Kim et al. Identifying causal genes and dysregulated pathways in complex diseases PLoS Comput. Biol. 7 2011 e1001095
97. F. Prinz et al. Believe it or not: how much can we rely on published data on potential drug targets? Nat. Rev. Drug Discov. 10 2011 712
98. S. Cha et al. In situ proteomic analysis of human breast cancer epithelial cells using laser capture microdissection: annotation by protein set enrichment analysis and gene ontology Mol. Cell. Proteomics 9 2010 2529 2544
99. J. Mestas, and C.C.W. Hughes Of mice and not men: differences between mouse and human immunology J. Immunol. 172 2004 2731 2738
100. J. Seok et al. Genomic responses in mouse models poorly mimic human inflammatory diseases Proc. Natl. Acad. Sci. U.S.A. 110 2013 3507 3512
101. R. Chen et al. Personal omics profiling reveals dynamic molecular and medical phenotypes Cell 148 2012 1293 1307
102. H.W. Rhee et al. Proteomic mapping of mitochondria in living cells via spatially restricted enzymatic tagging Science 339 2013 1328 1331
103. R. Karchin et al. Identification of aberrant pathway and network activity from high throughput data Pac. Symp. Biocomput. 18 2013 103 110
104. F. Azuaje et al. Drug-target network in myocardial infarction reveals multiple side effects of unrelated drugs Sci. Rep. 1 2011 52
105. L. Yang, and P. Agarwal Systematic drug repositioning based on clinical side-effects PLoS ONE 6 2011 e28025
106. S. Mizutani et al. Relating drug-protein interaction network with drug side effects Bioinformatics 28 2012 i522 i528
107. E. Lounkine et al. Large-scale prediction and testing of drug activity on side-effect targets Nature 486 2012 361 367
108. J. Mestres et al. Data completeness: the Achilles heel of drug-target networks Nat. Biotechnol. 26 2008 983 984
109. S. Zhao, and R. Iyengar Systems pharmacology: network analysis to identify multiscale mechanisms of drug action Annu. Rev. Pharmacol. Toxicol. 52 2012 505 521
110. C.M. McHale et al. Toxicogenomic profiling of chemically exposed humans in risk assessment Mutat. Res. 705 2010 172 183